Mild-to-moderate active luminal Crohn's disease

Digestion. 2007;76(2):92-8. doi: 10.1159/000111022. Epub 2008 Feb 7.


The management of luminal Crohn's disease, the most common form of initial presentation of the disease, depends on the location and the severity of the disease. Mild-to-moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients inversely correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies has not been thoroughly evaluated in patients with mild disease.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Crohn Disease / drug therapy*
  • Crohn Disease / epidemiology
  • Crohn Disease / pathology*
  • Disease Progression
  • Evidence-Based Medicine
  • Humans
  • Incidence
  • Mesalamine / therapeutic use
  • Prevalence
  • Quality of Life
  • Severity of Illness Index


  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Mesalamine